Primary percutaneous coronary intervention: Different outcome for different subgroups?

Journal of Cardiovascular Medicine

Volumn 10, Issue SUPPL. A, 2009, Pages

  Savonitto, Stefano ^a   Briguori, Carlo ^b,c   Ribichini, Flavio ^d   Tomai, Fabrizio ^e   Piccaluga, Emanuela ^f  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Clinica Mediterranea   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e EUROPEAN HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute coronary syndrome; High risk subgroups; Management; Reperfusion therapy; STEMI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; IOBITRIDOL; IODIXANOL; IOHEXOL; IOPAMIDOL; IOXAGLIC ACID; PLACEBO;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ANGIOPLASTY; BLEEDING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST INDUCED NEPHROPATHY; DRUG ELUTING STENT; DRUG MEGADOSE; ELDERLY CARE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE REPERFUSION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSPECIFIED SIDE EFFECT; AGE; AGED; CHRONIC KIDNEY FAILURE; FEMALE; MALE; MIDDLE AGED; MORTALITY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 73949159279     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000362041.25767.bc     Document Type: Conference Paper

References (52)

1. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44:E1-E211.
2. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115:2570-2589.
3. Di Chiara A, Chiarella F, Savonitto S, Lucci D, Bolognese L, De Servi S, et al. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003; 24:1616-1629.
4. White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries trial. Circulation 1996; 94:1826-1833.
5. Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2004; 110:1598-1604. (Pubitemid 39297982)
6. DeGeare VS, Stone GW, Grines L, Brodie BR, Cox DA, Garcia E, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J Cardiol 2000; 86:30-34.
7. French WJ. Trends in acute myocardial infarction management: use of the National Registry ofMyocardial Infarction in quality improvement. Am J Cardiol 2000; 85:5B-9B; discussion 10B-12B.
8. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336:1621-1628.
9. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27:779-788.
10. Grines CL. SENIOR PAMI. A prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction. In: 17th Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium. Washington, DC; 16-21 Oct 2005.
11. Wallentin L, Stenestrand U. RIKS-HIA 10 years 1995-2004: RIKS-HIA; 2005. http://www.ucr.uu.se/rikshiaint/document/RiksHia-Report-2004- EN1.pdf
12. Schiele F, Meneveau N, Seronde MF, Descotes-Genon V, Oettinger J, Ecarnot F, et al. Changes in management of elderly patients with myocardial infarction. Eur Heart J 2009; 30:987-994.
13. Olivari Z, Di Pede F, Schievano E, Brocco S, Ramondo A, La Vecchia L, et al. Hospital epidemiology of ST-segment elevation myocardial infarction and feasibility of primary percutaneous coronary intervention in an interhospital network: data from a multicenter, prospective and observational study VENERE (VENEto acute myocardial infarction REgistry [in Italian]. Ital Heart J 2005; 6 (Suppl. 6):57S-64S.
14. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, et al. Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1063-1070.
15. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625-634.
16. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, Rao SV, et al. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005; 46:1490-1495.
17. Mak KH, Effron MB, Moliterno DJ. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Drugs Aging 2000; 16:179-187.
18. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218-2230.
19. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383.
20. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:480-486.
21. American Heart Association. 2002 Heart and stroke statistical update. Dallas, Texas: American Heart Association; 2002.
22. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117:e25-e146.
23. Biswas MS, Calhoun PS, Bosworth HB, Bastian LA. Are women worrying about heart disease? Womens Health Issues 2002; 12:204-211.
24. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007; 115:1481-1501. (Pubitemid 46648385)
25. Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation 2005; 111:940-953.
26. Champney KP, Frederick PD, Bueno H, Parashar S, Foody J, Merz CN, et al. The joint contribution of sex, age and type of myocardial infarction on hospital mortality following acute myocardial infarction. Heart 2009; 95:895-899.
27. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, et al. Sex differences in medical care and early death after acute myocardial infarction. Circulation 2008; 118:2803-2810.
28. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, et al. Sexrelated differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 2009; 95:20-26.
29. Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2005; 111:1611-1618.
30. Milcent C, Dormont B, Durand-Zaleski I, Steg PG. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database. Circulation 2007; 115:833-839.
31. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339:799-805.
32. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
33. Hemmelgarn BR, Southern DA, Humphries KH, Culleton BF, Knudtson ML, Ghali WA. Refined characterization of the association between kidney function and mortality in patients undergoing cardiac catheterisation. Eur Heart J 2006; 27:1191-1197.
34. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108:2769-2775.
35. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006; 70:2021-2030.
36. Marenzi G, Moltrasio M, Assanelli E, Lauri G, Marana I, Grazi M, et al. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty. Am Heart J 2007; 153:755-762.
37. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med 1995; 332:647-655.
38. Romano G, Briguori C, Quintavalle C, Zanca C, Rivera NV, Colombo A, et al. Contrast agents and renal cell apoptosis. Eur Heart J 2008; 29:2569-2576.
39. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44:1393-1399.
40. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329-336.
41. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido- Allen DA, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999; 33:403-411.
42. Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonatebased hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med 2009; 7:23.
43. Recio-Mayoral A, Chaparro M, Prado B, Cozar R, Mendez I, Banerjee D, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007; 49:1283-1288.
44. Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W Jr, Vlietstra RE, et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000; 101:2172-2177.
45. Bertrand ME, Esplugas E, Piessens J, Rasch W. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: a multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators. Circulation 2000; 101:131-136.
46. Bolognese L, Falsini G, Grotti S, Limbruno U, Liistro, Carrera A, et al. The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Primary Angioplasty for Acute Myocardial Infarction Study: Design and Rationale of the CONTRAST-AMI study. J Cardiovasc Med 2009; in press.
47. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491-499.
48. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007; 115:3189-3196.
49. Freeman RV, O'Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90:1068-1073.
50. Meyer M, LeWinter MM, Bell SP, Chen Z, Selby DE, Singla DK, et al. N-acetylcysteine-enhanced contrast provides cardiorenal protection. JACC Cardiovasc Interv 2009; 2:215-221.
51. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116:745-754.
52. Briguori C, Airoldi F, Chieffo A, Carlino M, Montorfano M, Colombo A. Renal function and drug-eluting stent. Int J Cardiol 2009; Jan 13. [Epub ahead of print].